NCT00205634

Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: Wake Forest University · Academic / Other
• Sex: All
• Age: 6 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether Biaxin (clarithromycin) improves sputum abnormalities, lung function, and overall feeling of well-being in people with cystic fibrosis (CF). Biaxin is an antibiotic commonly used for the treatment of respiratory infections in people who do not have CF, and is sometimes used in CF patients as well. Studies done in a disease called diffuse panbronchiolitis (which is similar to CF) and some preliminary studies that have been done in CF patients suggest that Biaxin might have a beneficial effect on CF sputum in ways unrelated to its antibiotic activity.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	Biaxin ( clarithromycin)

Timeline

• Start date: 2000-12-01
• Primary completion: 2004-10-01
• Completion: 2004-10-01
• First posted: 2005-09-20
• Last updated: 2018-08-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study